SEOUL, July 14 (Yonhap) - Vuno, an artificial intelligence (AI)-based cancer treatment software company, and Oncosoft, a medical AI solution provider, announced Thursday that they had signed a business agreement to research and develop precision cancer treatment medical AI solutions jointly.
The two companies plan to research AI precision medical solutions and develop and commercialize new products based on their R&D and commercialization capabilities in areas such as medical AI and radiation therapy. Vuno will participate in a capital increase of Oncosoft to solidify the partnership.
Vuno has entered into this agreement to expand its business to precision medicine as well as AI-based cancer diagnostic aids and lesion quantification technologies that have already been successfully commercialized.
Oncosoft was founded in 2019 by Dr. Jinsung Kim, a professor of radiation oncology at Yonsei Seberance Cancer Hospital, and is developing AI software to streamline the radiation therapy workflow.
The software is expected to reduce the process of radiation therapy, including tumor delineation, treatment planning, and dose monitoring, which takes an average of seven days, to 20 minutes or less.
Radiation therapy is a treatment that delivers high-energy radiation from multiple directions to a tumor target to stop cancer cells from dividing and multiplying while minimizing damage to normal cells. Unlike surgery, it is characterized by the non-invasive ability to preserve the structure and function of organs and does not cause pain in most cases.
